Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Placental insufficiency is the source of preeclampsia (PE) and intrauterine growth
retardation (IUGR). Current data demonstrate a significant beneficial effect of prophylactic
use of aspirin on the recurrence of placental insufficiency and its complications, mainly
preeclampsia, when started early in pregnancy. However, there is a significant heterogeneity
in medical practice in Canada and around the world in terms of the dose of aspirin used.
The objectives of this study are: 1) Evaluate whether a dose of 160 mg of aspirin is
associated with greater improvement in placental function assessed by biochemistry (sFlt-1
and endoglin) and ultrasound (uterine artery Doppler) than a dose of 80 mg in women with a
history of PE, 2) Assess whether the change is dependent on platelet aggregation measured by
a test used in several Canadian centers (PFA-100).
Phase:
Phase 4
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Québec, CHU de Québec CHU de Quebec-Universite Laval